Compare · AMIX vs DXCM
AMIX vs DXCM
Side-by-side comparison of Autonomix Medical Inc. (AMIX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMIX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 6010.2x AMIX ($4.7M).
- Over the past year, AMIX is down 73.8% and DXCM is down 10.2% - DXCM leads by 63.6 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 4 for AMIX).
- DXCM has more recent analyst coverage (25 ratings vs 0 for AMIX).
- Company
- Autonomix Medical Inc.
- DexCom Inc.
- Price
- $0.39+3.26%
- $76.89+5.55%
- Market cap
- $4.7M
- $28.11B
- 1M return
- +4.64%
- +26.19%
- 1Y return
- -73.83%
- -10.22%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2005
- News (4w)
- 4
- 26
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest AMIX
- Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
- SEC Form 10-K filed by Autonomix Medical Inc.
- Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
- Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
- Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
- Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
- Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026
- SEC Form S-8 filed by Autonomix Medical Inc.
- Autonomix Medical to Present at LSI USA '26
- Autonomix Medical Selected for Best Innovation Competition at CRT 2026
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)